---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-137472"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:27:23.642675+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Organon Q3 revenue $1.6B (-1% YoY); adj. EPS $1.67; FY guidance narrowed; dividend $0.28

## Summary
- Revenue $1,600M, down 1% as-reported and 3% ex-FX YoY; net income from continuing ops $323M ($1.27 diluted EPS).
- Adjusted net income $424M ($1.67 diluted EPS); Adjusted EBITDA $636M (39.8% margin).
- Women's Health revenue $381M (-10% as-reported); Biosimilars +41%; Established Brands -6%.
- Board declares Q4 dividend $0.28/share, payable Dec 16, 2021, record Nov 22, 2021.
- Affirms FY guidance, narrows revenue range to $6.2B-$6.3B and Adj. EBITDA margin to 36.5%-37.5%.

## SEC filing metadata
- accession: 0001104659-21-137472
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465921137472/0001104659-21-137472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465921137472/tm2131080d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-137472
- JSON: https://secwatch.observer/filing/0001104659-21-137472.json
- Plain text: https://secwatch.observer/filing/0001104659-21-137472.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.